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Abbreviations  
 
 
ADH Anti-diuretic hormone 
ADNDI Autosomal dominant neurohypophyseal diabetes insipidus 
ALLN N-Acetyl-leucyl-leucyl-norleucinal 
AQP2 Aquaporin 2 
ATF 6 Activating transcription factor 6 
AVP  Arginine vasopressin 
b-ZIP Basic leucine zipper 
CFTR Cystic fibrosis transmembrane conductance regulator 
COP I Coat protein I 
COP II Coat protein II 
CPY* Mutated vacuolar enzyme carboxypetidase 
DI Diabetes insipidus 
E1 Ubiquitin activating enzyme 
E2 Ubiquitin-conjugating enzyme 
E3 Ubiquitin-protein ligase 
EDEM ER degradation-enhancing 1,2-mannosidase-like protein 
eIF2α Eukaryotic translation initiation factor 2 
ER Endoplasmic reticulum 
ERAD ER-associated degradation 
ERGIC ER-Golgi intermediate compartment 
ERSD ER storage disease 
ERSE ER stress response element 
Glc Glucose 
GlcNAc N-acetylglucosamine 
GRP Glucose-regulated protein 
GT UDP-glucose:glycoprotein glucosyltransferase 
JIK Jun N-terminal inhibitory kinase 
Man Mannose 
MRI Magnetic resonance imaging 
NP II Neurophysin II 
OST Oligosaccharyltransferase 
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RAP Receptor-associated protein 
RB Russell bodies 
S1P Site-1 protease 
S2P Site-2 protease 
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SRP Signal recognition particle 
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TRAM Translocating chain-associated membrane protein 
TRAP Translocon-associated protein 
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UBL Ubiquitin like domain 
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Summary 
 
 
The nonapeptide hormone, arginine vasopressin, plays a decisive role in the regulation of 
fluid balance by reducing free water clearance through reabsorption of water in the renal 
collecting ducts. Mutations in the gene encoding arginine vasopressin cause autosomal 
dominant neurohypophyseal diabetes insipidus, a disease characterized by excessive urine 
production and strong thirst. Post mortem examination of affected individuals suggests a 
selective degeneration of vasopressinergic neurons in the hypothalamus. On a molecular level, 
the disease is linked to a trafficking defect. Mutant vasopressin precursor is retained in the 
endoplasmic reticulum, while the wild-type is transported to mature secretory granules at 
synaptic processes. How this trafficking defect of the vasopressin precursor is interrelated 
with the degeneration of neurons is unknown. A plausible hypothesis is that mutant proteins, 
or degradation products thereof, are toxic to neurons. 
Accordingly, we analyzed the fate of mutant vasopressin precursor arrested in the 
endoplasmic reticulum of transfected cell lines. Proteasomal, but not lysosomal, inhibitors 
induced stabilization of mutant precursors and the accumulation of three distinct non-
glycosylated cytosolic species: pre-pro-vasopressin, pro-vasopressin, and an N-terminally 
truncated form. These results provide evidence that mutant precursor, after translocation into 
the ER lumen, is retrotranslocated to the cytosol and degraded by the proteasome. 
Furthermore, a fraction of the newly synthesized precursor, even of wild-type, was found not 
to be translocated, but to be synthesized into the cytosol due to inefficiency of the vasopressin 
signal peptide.  
In autosomal dominant neurohypophyseal diabetes insipidus, neurotoxicity may thus result 
from degradation intermediates and/or by ER retention directly. Both mistargeted and 
retrotranslocated proteins add to the cytosolic pool of these degradation products. 
Neurodegeneration might occur in heterozygous individuals once a critical concentration of 
toxic material is exceeded.  
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Introduction 
 
1. Diabetes insipidus 
1.1 Water regulation by the antidiuretic hormone 
 
Water homeostasis is critical to survival of cells and organisms. Accordingly, the balance of 
water uptake and excretion needs to be carefully controlled. We ingest water as part of our 
daily diet. Loss of water occurs during the maintenance of body temperature by sweating, or 
when removing waste products by either urination or defecation. Additional moisture is lost 
during exhalation, but the largest loss of fluid will ordinarily occur through urination. The 
amount of urine an individual produces varies depending on kidney activity, while the 
quantity of water filtered from the blood passing through the kidney remains relatively 
constant under physiological conditions. An adult human produces about 180 litres of primary 
filtrate per day, of which about 90% is held back by the proximal compartments of the 
nephron. The remaining 10% reach the distal collecting tubules, where water reabsorption is 
controlled by anti-diuretic hormone (ADH), also known as vasopressin (VP). ADH-dependent 
water reabsorption reduces the volume we excrete each day to an approximate 1% of the 
original primary filtrate. 
Vasopressin synthesis occurs in magno- and parvocellular neurons of the hypothalamus. 
Hypovolemia and/or hypernatremia stimulate release of vasopressin to the blood stream. 
Water reabsorption in the kidney is achieved via a G-protein coupled receptor cascade. 
Vasopressin from the bloodstream binds to the vasopressin receptor V2 (V2R) at the 
basolateral side of the cell in renal collecting ducts (Figure 1). This leads to an elevation of 
intracellular cAMP levels by the activation of adenylate cyclase and subsequent 
phosphorylation of the water channel aquaporin 2 (AQP2) at its cytoplasmic C-terminus by 
protein kinase A. Consequently, transport vesicles containing AQP2 fuse with the apical 
plasma membrane and permit increased reabsorption of water from the collecting ducts. In 
parallel, synthesis of AQP2 is induced. Water molecules leave the cell through aquaporin 3 
and 4 channels at the basolateral membrane. Removal of AVP from the V2R results in the 
internalisation of AQP2, ending the cycle (Rutishauser and Kopp, 1999; Levin et al., 2001). 
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Rutishauser and Kopp (1999) 
 
FIG. 1. Arginine vasopressin (AVP) binds to its receptor and activates protein kinase A (PKA), inducing fusion 
of aquaporin 2 containing vesicles with the plasma membrane. Water resorption persists as long as AVP remains 
bound to its receptor. Subsequently AQP2 is reinternalized. 
 
 
1.2 Disorders of water homeostasis 
 
Failure to efficiently concentrate urine will lead to polyuria and consequently polydipsia. This 
clinical condition, characterized by the production of large quantities of dilute urine, is known 
as diabetes insipidus (DI). Three mechanisms are known to cause DI. Deficiency of VP itself 
causes neurohypophyseal diabetes insipidus. Renal resistance to the antidiuretic action of VP, 
e.g. due to injury of the nephron or to mutations in the VP receptor or the aquaporins, results 
in nephrogenic diabetes insipidus. Finally, inappropriate and excessive drinking without a 
somatic cause leads to dipsogenic diabetes insipidus.  
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DI and its subtypes can be diagnosed by a water deprivation test. It compares plasma 
osmolality with urine osmolality during a defined time period of water deprivation, and 
assesses the response of these parameters to exogenous VP administration. Neurohypophyseal 
diabetes insipidus results from acquired pathologies affecting the vasopressinergic cells, such 
as trauma, infiltrating or inflammatory diseases, or tumors. Rarely, the disease is congenital 
due to mutations in the gene encoding pre-pro-vasopressin. This disease is called autosomal 
dominant neurohypophyseal diabetes insipidus (ADNDI). Although it is rather rare, the 
disorder shows a high penetrance with symptoms beginning weeks to months after birth. 
Presentation of neurohypophyseal diabetes insipidus implies destruction or loss-of-function of 
more than 80% of magnocellular neurons. Further clinical information may be obtained from 
magnetic resonance imaging (MRI). In normal subjects the posterior pituitary shows a high 
intensity signal on T1-weighted images. Absence of such a signal has been correlated with 
neurohypophyseal DI, although studies have failed to display a strict cosegregation of 
morphological abnormalities and clinical symptoms (Miyamoto et al., 1991; Rutishauser et 
al., 1996; Gagliardi et al., 1997).  
 
 
1.3 Vasopressin: gene structure and mutational analysis in ADNDI 
 
The vasopressin gene, located on chromosome 20p13, consists of three exons (Figure 2). The 
first exon encodes a signal peptide of 19 amino acids, followed by the 9 amino acid hormone, 
a 3 amino acid linker, and the 9 N-terminal amino acids of neurophysin II (NPII), 
vasopressin’s carrier protein. Exon 2 encodes 67 amino acids, which form the central part of 
NPII. Exon 3 constitutes the C-terminal 17 amino acids of NPII, a single amino acid linker, 
and a C-terminal glycopeptide of 39 amino acids, also known as copeptide, bearing a single 
N-linked glycosylation site. 
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FIG. 2.Gene structure and the spliced precursor of vasopressin. 
 
 
Mutations in the VP-NPII gene cause autosomal dominant neurohypophyseal diabetes 
insipidus. The phenotype is not linked to a specific mutation or set of mutations in the 
vasopressin gene, and no hot spots have been determined. More than 40 mutations spread 
over all three exons are known to cause a similar clinical phenotype (Figure 3 and Table I). 
The observed mutations are located mainly in neurophysin II, although some have been found 
in the signal peptide and the hormone itself, including the only mutation known to cause 
recessive inheritance. This exception likely results from the reduced binding affinity of the 
mutant vasopressin to its receptor in the collecting duct (Willcutts et al., 1999). No mutations 
have been found in the copeptide so far. Interestingly, severity of the phenotype appears 
largely independent of a particular mutation. Moreover, individuals carrying the same mutant 
may exhibit various degrees of polyuria, and symptoms may regress with age (Rutishauser et 
al., 1996). 
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FIG. 3. Scheme depicting the domains of pre-pro-vasopressin (above) and the sites of known mutations (below). 
Processing sites are marked by triangles. Lines indicate domain borders. Asterisks mark sites of a known 
mutation. Note that more than one mutation has been found at some sites. 
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Table I 
 
Exon Nucleotide # Base 
Mutation 
Amino Acid # Amino Acid 
Substitution 
Kindred Reference 
 
1 225  A?G  SP -19 to -16  del MPDT 1 Christensen (2004) 
 227  G?A  SP -19 to -16  del MPDT 1 Christensen (2004) 
 227  del G  SP -19 to -16  del MPDT 1 Rutishauser (1996) 
 274  C?T  SP -3  S?F 1 Rittig (1996) 
 279  G?A  SP -1  A?V 8 Ito (1993) 
McLeod (1993) 
Rittig (1996) 
Calvo (1998) 
Siggaard (1999) 
Boson (2003) 
Christensen (2004) 
 280  C?T  SP -1  A?T 3 Rittig (1996) 
Heppner (1998) 
Christensen (2004) 
 285  T?C  VP 2  Y?H 2 Rittig (1996) 
Rittig (2002) 
 287-289  del CTT  VP 3  del F 1 Wahlstrom (2004) 
 
2 1730  G?C  NP 14  G?R 1 Rittig (1996) 
 1740  G?T  NP 17  G?V 1 Bahnsen (1992) 
 1748  C?T  NP 20  R?C 1 Rittig (1996) 
 1751  T?C  NP 21  C?R 1 Gonking (1997) 
 1757  G?C  NP 23  G?R 3 Heppner (1998) 
Rutishauser (2002) 
Christensen (2004) 
 1757  G?A  NP 23  G?R 1 Calvo (1999) 
 1758  C?T  NP 23  G?V 1 Gagliardi (1997) 
 1761  C?T  NP 24  P?L 1 Repaske (1994) 
 1772  T?C  NP 28  C?R 1 Hansen (1997) 
 1773  G?A  NP 28  C?Y 1 Skordis (2000) 
 1774-1776  del CGC  NP 28/29  del C/ A?W 1 Fluck (2001) 
 1797  T?C  NP 36  V?A 1 Christensen (2004) 
 1824-1829  del AGG  NP 47  del E 7 Yuasa (1993) 
Rittig (1996) 
Mahoney (2002) 
Christensen (2004) 
Ye (2005) 
 1829  G?A  NP 47  E?K 1 Miyakoshi (2004) 
 1830  A?G  NP 47  E?G 2 Rittig (1996) 
Christensen (2004) 
 1839  T?C  NP 50  L?P 1 Rittig (1996) 
 1857  C?T  NP 56  S?F 1 Grant (1998) 
 1859  G?A  NP 57  G?S 2 Ito (1991) 
Rittig (1996) 
 1859  G?C  NP 57  G?R 1 Rittig (1996) 
 1872  G?C  NP 61  C?S 2 Rittig (1996) 
Bullmann (2002) 
 1872  G?A  NP 61  C?Y 2 Grant (1998) 
Rutishauser (2002) 
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 1873  C?A  NP 61  C?X 3 Rittig (1996) 
Grant (1998) 
Christensen (2004) 
 1874  G?T  NP 62  G?W 1 Nagasaki (1995) 
 1883  G?T  NP 65  G?C 2 Rittig (1996) 
Christensen (2004) 
 1884  G?A  NP 65  G?D 1 Christensen (2004) 
 1884  G?T  NP 65  G?V 2 Ueta (1996) 
Rauch (1996) 
 1886  C?T  NP 66  R?C 1 Rutishauser (1999) 
 1887  G?C  NP 66  R?P 1 Mundschenk (2001)
 1889  T?G  NP 67  C?G 1 DiMeglio (2001) 
 1891  C?A  NP 67  C?X 1 Nagasaki (1995) 
 1907  T?G  NP 73  C?G 1 Christensen (2004) 
 1908  G?T  NP 73  C?F 1 Santiprabhob 
(2002) 
 1910  T?C  NP 74  C?R 1 Rutishauser (2002) 
 1911  G?A  NP 74  C?Y 1 Fujii (2000) 
 
3 2094  C?A NP 79  C?X 1 Rittig (1996) 
 2101  G?T NP 82  E?X 2 Calvo (1998) 
 2106-2107  CG?GT NP 83  E?X 2 Rittig (1996) 
Bullmann (2002) 
 2110  T?G NP 85  C?G 2 Abbes (2000) 
Nijenhuis (2001) 
 2110  T?C NP 85  C?R 1 Abbes (2000) 
 2112  C?G NP 85  C?W 1 Christensen (2004) 
 2116  G?T NP 87  E?X 1 Rittig (1996) 
 
X = stop codon 
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1.4 ER retention of mutant VP precursor 
 
Like many secreted molecules, vasopressin is cotranslationally targeted to the endoplasmic 
reticulum (ER). Once the N-terminal pre-pro-hormone has entered the ER, signal peptidase 
removes the signal peptide. The folding of the pro-hormone is assisted by chaperones and the 
binding of vasopressin to the pocket of folded neurophysin II stabilizes dimerization of the 
pro-hormone (de Bree and Burbach, 1998). In addition, the copeptide is modified by 
attachment of a glycan to asparagine at position 5. If quality control is passed, the hormone 
travels via the ER-Golgi intermediate compartment (ERGIC) to the Golgi apparatus, where 
the glycan is further modified. At the trans-Golgi network (TGN), the pro-hormone is sorted 
to the regulated secretory pathway. Immature secretory granules containing higher oligomers 
of pro-vasopressin bud off from the TGN, and as they mature, prohormone convertase 1 
cleaves the prohormone and frees the vasopressin peptide. Mature secretory granules travel 
along the axon to the cell periphery and are stored near the synapse for subsequent regulated 
release. Vasopressin circulates freely in the blood stream, although it does bind to specific 
receptors on platelets. Circulating vasopressin has a half-life of 5 to 15 minutes. Endothelial 
and circulating endo- and amino-peptidases are responsible for its eventual degradation, and 
plasma levels are low under basal conditions. 
 
Several groups have studied the effect of the mutations on pre-pro-hormone trafficking using 
heterologous expression systems. 
Stable expression of the wild-type and a mutant (G17V) in the pituitary cell line AtT-20 
showed a distinct difference in processing and secretion of the molecules (Olias et al., 1996). 
The wild-type precursor was correctly glycosylated and processed, and NPII was detected in 
the culture medium. The mutant was core-glycosylated but remained endoglycosidase H-
sensitive, indicating that the protein did not reach the trans-Golgi network. Secretion was 
drastically reduced. Immunofluorescence studies showed that NPII in cells expressing the 
wild-type was concentrated in the tips of the cell processes where secretory granules 
accumulate. In G17V cells, NPII staining was restricted to the ER, determined by 
colocalization with the ER-resident protein BiP. 
Beuret et al. (1999) expressed the ΔG227 mutation, leading to a truncated signal peptide, in 
COS-7 cells. Glycosylation of the resulting precursor showed the truncated signal to be 
functional for ER-import. However, most of the precursor was observed with a higher 
apparent molecular weight, suggesting a failure in signal peptide cleavage. The mutant 
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precursor was almost completely retained in the ER, corroborated by costaining for the ER 
resident protein p63. 
Nijenhuis et al. (1999) studied a variety of mutants by stably expressing them in the 
neuroendocrine cell line Neuro2a and the rat pheochromocytoma cell line PC12/PC2. When 
comparing G14R, E47R, ΔE47, G57S, and G65V to the wild-type, all mutants were found to 
be impaired in processing and secretion, albeit to different extents (in decreasing order of 
impairment: G65V≥G14R>ΔE47≥E47G>G57S). Sensitivity to endoglycosidase H indicated 
retention of the precursors in the ER. Immunofluorescence studies using transiently 
transfected Neuro2a cells demonstrated that the mutant prohormone was found in large 
accumulations in the ER, which colocalized with the ER marker protein disulfide isomerase 
(PDI). 
Analogous studies with the E87X mutant in PC12/PC2 and the mouse pituitary cell line AtT-
20 also showed reduced processing and secretion and colocalization with PDI (Nijenhuis et 
al., 2000). 
Expression studies in PC12/PC2 cells using wild-type vasopressin and the C85G mutant 
confirmed previous observations. Processing and secretion was only observed for the wild-
type (Nijenhuis et al., 2001). The mutant was retained in the ER, as indicated by 
endoglycosidase H sensitivity. Transient transfection of Neuro2a cells demonstrated that the 
mutant was not only confined to the normal reticular ER. Costaining with PDI showed these 
areas to represent enlarged ER subcompartments. Such large areas of altered ER morphology 
could be responsible not only for severe dysfunction but also for death of the host cells in vivo 
(Aridor and Hannan, 2000; Rutishauser and Spiess, 2002). 
Siggaard et al. (1999) examined the signal peptide mutant A(-1)T in Neuro2a cells. They 
observed an 8-fold reduction in vasopressin secretion when compared to the wild-type, 
accompanied by the accumulation of improper signal cleavage. The precursor was found to 
colocalize with glucose-regulated protein 78, indicating an ER localization. 
 
Although the degree of retention varies among different mutants, inefficient ER exit leading 
to reduced secretion of mutant hormone precursors apparently is a common denominator in 
the pathogenesis of ADNDI. In order to understand the processes leading to this trafficking 
defect, we need to briefly look at the mechanisms involved in secretion of proteins from the 
cell. 
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2. The secretory pathway 
 
Hormones are molecules acting on target tissues which are typically remote from the site of 
production. In order for secretion to occur, the proteins must thus enter the secretory pathway. 
While all cells possess the means to constitutively release proteins form the cell, endocrine 
cells need to regulate hormone release in response to a specific stimulus. Therefore, they are 
endowed with an additional release mechanism, the regulated secretory pathway (Figure 4). 
 
If a protein is to be released from the cell, it is targeted to the ER. In mammalian cells this is a 
cotranslational process. As the newly synthesized polypeptide emerges into the ER lumen, it 
may be modified by core glycosylation. In addition, chaperones promote proper folding. 
Before the secretory protein can leave the ER it needs to pass quality control, a mechanism 
which prevents further transport of incorrectly folded precursors, such as proteins which are 
either non-functional or thermo-labile because they have not attained their native 
conformation. The protein then travels via the ERGIC to the Golgi apparatus. Here further 
modifications such as complex glycosylation or sulfation may occur. The TGN is the 
compartment where proteins destined for regulated secretion are segregated from those taking 
other pathways. The hormone precursors are sorted to immature secretory granules, which 
mature as they travel to the cell periphery. During the maturation process, the pro-hormones 
are activated by pro-hormone convertases. The mature secretory granules are then stored near 
the cell periphery, from where they can be rapidly released in response to the proper stimuli. 
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Bonifacino and Glick (2004) 
 
FIG. 4. Schematic representation of the intracellular transport system. Some vesicle budding and cargo selection 
steps are mediated by known coat components (e.g. coat proteins I (COPI) or II (COPII), or clathrin). Others, 
such as sorting to immature secretory granules, remain to be determined. Constitutive secretory pathway 
(yellow) and regulated secretory pathway (green) are highlighted. 
 
 
2.1 ER entry/translocation 
 
Protein secretion is initiated by targeting the molecule to the ER. Proteins possess signal 
sequences, exhibiting a stretch of hydrophobic amino acids. As these amino acids emerge 
from the ribosome, they are recognized and bound by the signal recognition particle (SRP). 
Binding of SRP attenuates translation and by the binding of SRP to the SRP receptor, the 
nascent peptide chain is targeted to the ER. Entry into the ER lumen is conferred by the 
translocon, a gated channel formed by the heterotrimeric sec61 αβγ complex (Figure 5). 
Concurrent with entry, signal peptidase cleaves the signal peptide. 
Entry into the ER, however, depends on additional components. Reconstitution experiments 
using lipid vesicles demonstrated the requirement of translocating chain-associated membrane 
protein (TRAM) beside the heterotrimeric sec61 complex and SRP receptor (Gorlich and 
Rapoport, 1993). 
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Johnson and van Waes (1999) 
 
FIG. 5. Ribosome docked to the translocon complex. Only one of the Sec61 heterotrimers (Sec61αβγ) is 
depicted. SP: signal peptidase, OST: oligosaccharyltransferase, TRAM: translocating chain-associated 
membrane protein 
 
 
While these are the essential components required for translocation, some substrates such as 
the prion protein are inefficiently or improperly translocated using this minimal system. 
Translocon-associated protein (TRAP) complex was found to alleviate this inefficiency (Fons 
et al., 2003). Other substrates were found to be only partially dependent on TRAP. Analysis 
of their respective signal sequences implied that this dependence was linked to a functional 
property of the signal, rather than a physical parameter such as hydrophobicity. The efficiency 
of the signal in targeting the nascent chain to the ER, specifically gating activity, correlates 
inversely with TRAP dependence. The gating step commits the substrate to initiate 
translocation of its N-terminus. Substrates whose signal sequence shows weaker gating 
activity exhibit a stronger requirement of TRAP during their translocation than those with 
stronger gating activity. 
 
The signal sequence itself also carries information which determines the efficiency of ER 
import. Critical factors are the length of the hydrophobic region in the signal, the overall 
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distribution of charged amino acids with respect to the hydrophobic region, and the position 
of the signal in relation to the start codon, i.e. the size of the N-terminal region synthesized 
prior to the signal (Wahlberg and Spiess, 1997; Goder and Spiess, 2001). 
 
 
2.2 Quality control in the ER 
 
Transfer of nascent chains to the ER via the Sec61 translocon is accompanied by the binding 
of several ER resident proteins which stabilize and modify them. Quality control in the ER 
can be subdivided into different levels. Primary quality control applies to all proteins, working 
in a general fashion. Secondary quality control, on the other hand, is restricted to selected 
categories of proteins. 
Shared structural and biophysical features distinguishing native from non-native conformation 
are the basis for primary quality control. These include exposed hydrophobic regions, 
unpaired cysteine residues, and the tendency to aggregate. The molecular chaperones involved 
in primary quality control include members of the heat shock protein family such as 
BiP/GRP78 and glucose-regulated protein 94 (GRP94), the lectins calnexin and calreticulin, 
and the thiol-disulfide oxidoreductases PDI and Erp57. Acting in concert, these molecules 
ensure the retention of incompletely folded precursors and unassembled oligomers. Correctly 
folded proteins are not detected by the system and are free to leave the ER.  
The cues allowing the targeting of these chaperones to non-native peptide chains have only 
been partially determined. Some information is available for BiP as well as for the 
calnexin/calreticulin system. In vitro data suggests that BiP binds heptapeptides bearing 
aliphatic amino-acid side chains in alternating positions (Flynn et al., 1991). The binding of 
BiP is limited by the heptapetides accessibility. Only exposed areas bearing the sequence are 
used in protein folding. 
The calnexin/calreticulin cycle is involved in the quality control of glycoproteins (Figure 6). 
Improperly folded material is retained in the ER, and if failure to reach the native 
conformation persists, eventually targeted for degradation. The two lectins interact with 
trimmed intermediates of N-linked core glycans on nascent protein chains. They recognize the 
Glc1Man7GlcNAc2 structure, where Glc is glucose, Man is mannose, and GlcNAc is N-
acetylglucosamine. Either the soluble calreticulin, the transmembrane calnexin, or both lectins 
together are associated with most glycoproteins synthesized in the ER. Both lectins form 
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complexes with the thiol-disulfide oxidoreductase Erp57. Erp57 forms transient disulfide 
bonds with calnexin/calreticulin-bound glycoproteins. 
Two independent enzymes mediate the timer for retention and release in the control cycle. 
Glucosidase II hydrolyses glucose from monoglucosylated core glycans and permits 
dissociation of the glycoprotein from the respective lectin. UDP-glucose:glycoprotein 
glucosyltransferase (GT) reglucosylates the substrate if the glycoprotein is improperly folded 
and thus allows for reassociation of the substrate with the lectin (Parodi, 2000). GT serves as 
a folding sensor which prevents exit of improperly folded protein by tagging chains with 
glucose. In vitro experiments suggest the presence of hydrophobic amino-acid clusters as the 
recognition motif for reglucosylation (Caramelo et al., 2003). The cycle of deglucosylation 
and reglucosylation continues until the protein has reached the proper conformation, or until 
the chain is targeted for degradation. 
Trimming of a mannose from the middle branch of the glycan by ER α1,2-mannosidase I 
targets glycoproteins for degradation. Removal of the mannose leads to an association of the 
oligosaccharide with ER degradation-enhancing 1,2-mannosidase-like protein (EDEM). ER 
α1,2-mannosidase I acts more slowly than glucosidase II and GT. Only terminally misfolded 
proteins which have failed to attain proper conformation during multiple cycles of 
deglucosylation and reglucosylation are removed from the calnexin/calreticulin cycle and 
eliminated (Molinari et al., 2003). 
 
Acting in concert with the primary quality control mechanisms, select subsets of proteins are 
subject to additional scrutiny. Secondary quality control relies on specific recognition 
mechanisms for individual proteins or protein families (Figure 7). The proteins involved in 
secondary quality control, which is often cell type specific, have been grouped into three 
classes: ‘outfitters’, ‘escorts’, and ‘guides’ (Herrmann et al., 1999). 
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Ellgaard and Helenius (2003) 
 
FIG. 6. Scheme depicting the steps of quality control undertaken by an N-linked glycoprotein. The processing of 
the core glycan tree helps ensure folding fidelity. Properly folded proteins will eventually leave the ER via exit 
sites, while terminally misfolded material is targeted for degradation via the cytosolic proteasome pathway. M 
(mannose), G (glucose) 
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Outfitters are ER resident proteins which help establish or maintain secretion competence of 
secretory proteins. They function as folding catalysts and chaperones. One example is a yeast 
integral ER membrane protein, Shr3p. While it is non-essential, it is necessary for proper 
trafficking of general amino acid permease to the plasma membrane. In its absence, the amino 
acid permeases are retained in the ER in an aggregated state (Kota and Ljungdahl, 2005). 
Escorts act similarly to outfitters, but they leave the ER and cycle to the Golgi. They include 
regulatory molecules which prevent premature activation of their substrates. Receptor-
associated protein (RAP) is a well-characterized example of this category. RAP binds and 
stabilizes newly synthesized receptors of the low-density lipoprotein receptor family. In the 
absence of RAP, premature binding of ligand to the receptor leads to receptor aggregation in 
the ER, followed by the degradation of the receptor-ligand complex. Ordinarily, the receptor-
RAP complex dissociates in the Golgi due to the lower pH, from where RAP cycles back to 
the ER (Bu and Schwartz, 1998) 
Guides or transport receptors, differ from the previous groups in that they provide information 
required for the selective uptake of cargo into transport vesicles. They bind to the secretory 
protein and interact directly or indirectly with the coat proteins, serving as adaptors which 
cycle between ER and Golgi. One well-known representative of the guides is the lectin 
ERGIC-53 which cycles between ER and Golgi. It serves as a transport receptor for certain 
proteins bearing high-mannose N-linked glycans (Appenzeller et al., 1999). 
 
 
 
Hermann and Schekman (1999) 
 
FIG. 7.Overview of the three different classes of accessory proteins involved in secondary quality control. 
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3. UPR and degradation of ER-retained proteins 
3.1 UPR 
 
The presence of irrevocably misfolded proteins in the ER is detrimental to the cell over a 
prolonged time period. The material interferes with proper trafficking by detaining 
components of the secretory pathway. Two processes aid eukaryotic cells to reduce this bulk 
load: ER-associated degradation (ERAD) and the unfolded protein response (UPR). The two 
responses are interconnected. Induction of UPR leads to an increase in ERAD capacity, while 
efficient ERAD is dependent on an intact UPR. Loss of ERAD results in a constitutive UPR 
induction. Loss of both ERAD and UPR strongly diminishes cell viability. 
One of the key classes of target genes of UPR is ER-resident chaperones. An increase in 
chaperone concentration helps to reduce the amount of unfolded proteins and precludes their 
aggregation.  
One of the elementary players in the unfolded protein response (Figure 8) is IRE1, an ER 
transmembrane glycoprotein (Liu and Kaufman, 2003; Zhang and Kaufman, 2004). It 
encompasses kinase and RNase activities in the cytoplasmic domain and a BiP interacting 
domain in the lumenal domain. BiP regulates IRE1 activity in an inverse manner. If unfolded 
proteins accumulate, the reduction of available BiP will result in the dimerization and 
autophosphorylation of IRE1. This in turn activates its RNase activity to catalyse the splicing 
of the mRNA of its substrate, transcription factor XBP1. The spliced product activates 
transcription of UPR target genes in the nucleus, many of which bear the mammalian ER 
stress element in the promoter region. 
Higher eukaryotic cells possess two additional UPR transducers: activating transcription 
factor 6 (ATF6), and the double-stranded RNA-activated protein kinase-like ER kinase 
(PERK). ATF6 possesses an N-terminal basic leucine zipper (b-ZIP) domain in the cytosol 
and a C-terminal ER-stress sensing domain in the ER lumen. Upon ER-stress, ATFα and 
ATFβ transit to the Golgi compartment where they are cleaved by site-1 protease (S1P) and 
site-2 protease (S2P) yielding cytosolic fragments which activate transcription of their target 
genes in the nucleus. These include ER-resident molecular chaperones and folding enzymes. 
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Zhang and Kaufman (2004) 
 
FIG. 8. Illustration of the interplay of IRE1 and ATF6 in promoting the expression of genes involved in both the 
unfolded protein response and the ER stress response via the respective response elements (UPRE and ERSE). 
 
 
Similar to IRE, PERK contains a lumenal stress-sensing domain and a cytosolic domain 
which phosphorylates the α-subunit of eukaryotic translation initiation factor 2 (eIF2α) under 
ER stress conditions (Figure 9). This phosphorylation leads to a general translation initiation 
attenuation, by reducing the formation of translation initiation complexes. The cell is, 
therefore, confronted with less newly synthesized proteins to fold, freeing chaperones to 
alleviate the current burden. Some mRNAs have a lower requirement for eIF2α. Their 
initiation complex is enhanced. One such example is ATF4, which serves not only as a 
feedback loop to reverse the phosphorylation of eIF2α and release translational attenuation, 
but also induces expression of CHOP upon longer UPR induction 
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Zhang and Kaufman (2004) 
 
FIG. 9. The effect of PERK on general translation, as well as its influence on induction of specific unfolded 
protein response genes. 
 
 
Prolonged activation of UPR leads to apoptotic cell death through two of the key players. 
Activated IRE1 recruits Jun N-terminal inhibitory kinase (JIK) and TRAF2. JIK activates 
apoptosis-signaling kinase 1, which in turn activates JNK and mitochondria/Apaf1-dependent 
caspases. TRAF2 release from the ER-associated apoptosis effector procaspase-12, permits 
the clustering and activation of caspase 12. It acts on caspase 9 which in turn activates caspase 
3, leading to apoptosis. 
The b-ZIP transcription factor CHOP induced by prolonged UPR via the eIF2α  and ATF4 
pathway activates caspase 3 through unknown intermediates leading to cell death (Kaufman, 
2002; Rutkowski and Kaufman, 2004). 
In yeast, activation of UPR induces transcription of several genes encoding ERAD proteins. 
Among these are ubiquitin-conjugating enzymes and ubiquitin-ligases, as well as a player of 
the (retro-)translocon, Hrd3. Studies in mammalian cells have demonstrated the necessity of 
the IRE-XBP1 signaling in regulating ERAD. Notably, induction of EDEM depends solely on 
this pathway. The efficient targeting of defective glycoproteins for degradation is therefore 
preceded by the activation of the unfolded protein response. 
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3.2 Retrotranslocation and degradation 
 
It has been estimated that as much as 30% of all newly synthesized proteins fail to pass 
quality control and need to be degraded (Schubert et al., 2000). Degradation of such 
misfolded proteins occurs outside the ER, thus requiring retrotranslocation. The protein 
destined for degradation is unfolded and exits the ER via the Sec61 complex (Wiertz et al., 
1996). Studies in yeast using mutated vacuolar enzyme carboxypetidase Y (CPY*) have 
elucidated many of the players involved in ER quality control and degradation (Kostova and 
Wolf, 2003). The transport from ER to the cytosol requires directionality. This might be 
mediated by the existence of two subsets of translocons with distinct compositions (Plemper 
et al., 1999). An important player for the removal of proteins from the ER to the cytosol is the 
Cdc48-Ufd1-Npl4 complex. Cdc48, p97 in mammals, belonging to the AAA ATPase family, 
is thought to pull the polypeptide chain through the pore in an ATP-dependent manner (Ye et 
al., 2001). Cdc48/p97 possesses a homo-hexameric ring structure. ATP hydrolysis promotes a 
strong conformational change. The emerging model suggests that the substrate emerges from 
the (retro-)translocon and becomes polyubiquitinated which allows binding of the Cdc48-
Ufd1-Npl4 complex. The conformational change of ATP hydrolysis then serves as the 
racheting mechanism providing unidirectionality of retrotranslocation.  
The tagging of proteins for degradation by ubiquitin is a multi-step process (Figure 10). 
Initially, ubiquitin is activated by a trans-esterification reaction requiring ATP which attaches 
it to a cysteine residue of ubiquitin activating enzyme (E1). The ubiquitin is subsequently 
transferred to the cysteine residue of a number of ubiquitin-conjugating enzymes (E2). These 
may transfer the ubiquitin directly to the substrate, although a third class of enzymes, 
ubiquitin-protein ligases (E3) are often involved as facilitators.  
Efficient delivery of proteins destined for degradation by the proteasome requires the 
presence of at least four ubiquitin moieties. The initial tag is extended by the attachment of 
additional ubiquitin to the preceding individual, usually to Lys48. The factors driving chain 
elongation have not been determined, although it is thought that the presence of additional 
component such as ubiquitylation factor E4 may be required. 
 
Delivery of ubiqitinated ER substrates occurs via Dsk2p and Rad23p (Medicherla et al., 
2004). Both proteins contain an N-terminal ubiquitin like domain (UBL) which may interact 
with the regulatory particle of the proteasome, and a C-terminal ubiquitin-associated domain 
(UBA) permitting the binding of polyubiquitin chains. Furthermore, Rad23p is thought to 
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play a role in deglycosylation of retrotranslocated glycoproteins by recruiting N-glycanase 
(Suzuki et al., 2001). 
The tagged substrate can bind to the 26S proteasome, the active degradation machinery, 
which deubiquitylates and unfolds it prior to degradation. The proteasome consists of the 20S 
core cylinder encompassing three catalytically active sites, and two 19S cap components 
responsible for recognition, binding and unfolding of ubiquitnated proteins. The cap consists 
of two functionally distinct parts, the base and the lid. The lid is necessary for 
deubiquitylation, freeing ubiquitin for another round of protein targeting. The base, consisting 
of a ring of six ATPases, both binds the tagged substrate and is thought to control access to 
the core in a similar manner to Cdc48 in retrotranslocation. 
 
 
 
Kostova and Wolf (2003) 
 
FIG. 10. The cycle undertaken by ubiquitin moieties used in tagging defective protein substrate for degradation 
(right). Schematic of the 26S proteasome with a linearized core segment. The active sites are marked in red 
(left). 
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4. Neurotoxicity hypothesis in ADNDI 
 
Mutations in a secretory protein like pro-vasopressin are likely to disturb correct folding, 
leading to retention of the protein by quality control. Such material will typically be degraded 
via the ubiquitin-proteasome pathway. In a heterozygous situation, one might expect the 
products of the wild-type allele to generate functional hormone, possibly of a reduced amount. 
However, the ADNDI mutations listed in Table I are all dominant. 
The mechanism explaining dominant inheritance has currently not been determined. 
Dimerization of pro-vasopressin, beginning in the ER, might explain retention of the product 
of the wild type allele only to some extent. The dimers consisting of one mutant and one wild 
type pro-hormone would likely fail to pass quality control, leading to their eventual 
degradation. Ito et al (1999) addressed this question when they epitope-tagged the wild-type 
and several mutants (A(-1)T, ΔE47, G57S, and C67X) and transfected them into human 
embryonic kidney cells, tsa 201. Crosslinking experiments revealed homo- and heterodimer 
formation between wild-type and mutant precursors. Furthermore, mutant precursor was 
found to inhibit trafficking of wild-type precursor from the ER to the Golgi apparatus. 
Ultimately, fewer vasopressin-containing secretory granules would be available for release at 
the cell periphery. However, the cell might adapt to the stronger demand for vasopressin by 
increasing expression of the gene. This would still result in a recessive phenotype. Notably, in 
similar experiments we were not able to confirm interaction of wild-type and mutant 
vasopressin precursor. 
Clinical data from individuals affected by diabetes insipidus has led to the development of a 
hypothesis about the aetiology of the disease. A decrease in circulating vasopressin paralleled 
by gliosis and hypocellularity of vasopressinergic neurons in the hypothalamus supported the 
notion that vasopressin mutants exert a toxic effect on their host cells, resulting in 
neurodegeneration. Support for this has been obtained from a limited number of post mortem 
studies (Hanhart, 1940; Gaupp, 1941; Braverman et al., 1965; Nagai et al., 1984; Bergeron et 
al., 1991). The selective destruction of the vasopressinergic magnocellular cells expressing 
mutant hormone would explain the dominant inheritance. Progressive cell death could 
account for the gradual development of clinical symptoms. How the mutants exert this 
detrimental effect remains the major open question in understanding the disease. 
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Support for the toxic hypothesis came from other heterologous expression studies. Ito et al. 
(1997) used stably transfected Neuro2a cells to asses an effect of vasopressin mutants on cell 
viability. Expression of mutant precursors (A(-1)T, ΔE47, G57S, and C67X) as such was not 
found to considerably affect growth of cells. When the cells were differentiated to a neuronal 
phenotype with valproic acid, however, viability was significantly reduced (C67X>A(-
1)T>G57S>ΔE47). Concurrent metabolic labeling and immunofluorescence studies confirmed 
the reduced secretion of mutant precursors and their accumulation within the ER observed by 
other groups  
Beuret et al. (1999) investigated the molecular consequences of the signal peptide mutant 
ΔG227. The mutation leads to translation initiation at an alternative ATG site, and displays 
reduced cleavage of the signal peptide. Transient transfection of COS-7 cells showed that the 
mutant was retained in the ER, and led to the formation of disulfide-linked aggregates. This 
was not surprising since the uncleaved signal contains an unpaired cysteine at position -11. 
Abolishing this unpaired cysteine did not alter the properties of the precursor protein. The 
double mutant ΔG227/ C(-11)S showed a similar phenotype as ΔG227, ER-localized 
precursor with an uncleaved signal peptide. To determine if uncleaved signal peptide 
interferes with disulfide bond formation, a cysteine residue in the vasopressin region of a 
wild-type precursor was altered to serine. The mutant, C6S, mimicked the aggregation 
phenotype, while being largely confined to the ER, despite proper cleavage of the signal 
peptide. Evidently, two independent processes, unpaired cysteine residues leading to aberrant 
disulfide bond formation, and interference of uncleaved signal peptide with correct folding, 
contribute to ER retention and formation of disulfide-linked aggregates. 
 
The accumulation of material in the ER is a phenomenon common to a group of disorders 
known as ER storage diseases (ERSD)(Rutishauser and Spiess, 2002). The material stems 
from nascent proteins failing quality control mechanisms in the ER. The disease phenotypes 
may result from the deficiency of a particular protein at its site of action, these are generally 
recessive diseases, or the mutant protein may exert a toxic effect. In the latter case, the mutant 
protein itself or one of its degradation products is detrimental to cell viability. Mutant proteins 
might aggregate and thus prevent further transport, detaining chaperones and clogging the ER 
until parts are rendered non-functional and need to be degraded.  
 
The use of animal models to examine ADNDI has met with limited success. A mutation (del 
G in NP 65, aka Brattleboro mutation) causes a frameshift leading to a strongly altered C-
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terminus. The precursor, bearing a poly Lys tail extending beyond the translational stop 
codon, causes a recessive disease phenotype in the rat (Schmale et al., 1984). Furthermore, the 
C67X mutation failed to reproduce a human disease phenotype in rats (Si-Hoe et al., 2000). 
Although the mutant was retained in the ER and water homeostasis was affected, no cell death 
or atrophy of magnocellular neurons was observed. Nevertheless, a recent paper supported the 
neurodegeneration hypothesis in ADNDI using a murine knock-in model (Russell et al., 
2003). Mice expressing the C67X neurophysin II mutation showed polyuria and polydipsia 
which worsened with progressing age. This was paralleled by loss of neurons in the 
supraoptic and paraventricular nuclei, along with an induction of the chaperone BiP in these 
cells. Furthermore, VP gene products could not be found in the neuronal projections, 
indicating a trafficking defect. The observed neurodegenereation, however, did not appear in 
mice expressing the common A(-1)T mutation.  
 
 
5. Aim of this thesis 
 
Experiments have shown ADNDI to be linked to a defect in protein trafficking. Protein 
precursors of mutant vasopressin were found to accumulate in the ER. In addition, 
experiments in our lab have demonstrated the formation of disulfide-linked aggregates formed 
by mutant- but not wild-type vasopressin precursor (Beuret et al., 1999). Whether the 
appearance of aggregates plays a direct or indirect role in the progression of the disease will 
warrant further examination. The accumulation of proteins in the ER has been linked to 
various classes of human disorders. Generally, terminally misfolded secretory protein 
precursors are removed from the ER by shuttling them into the ERAD pathway. Apparently, 
mutant vasopressin leads to toxic proteins or degradation fragments thereof, resulting in cell 
death. 
To investigate the basis of the neurotoxic effect, we decided to examine the mechanism of 
degradation of ADNDI mutant pro-vasopressin. 
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Results 
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Summary 
 
Mutations in the gene encoding the antidiuretic hormone arginine vasopressin cause 
autosomal dominant neurogenic diabetes insipidus. Autoptic data in affected individuals 
suggest that the neurons expressing mutant vasopressin undergo selective degeneration. 
Expression studies have shown that the mutants are retained in the endoplasmic reticulum, but 
how this trafficking defect is linked to neurotoxicity is unknown. One possibility is that 
unsecreted mutant precursors, or degradation products thereof, are cytotoxic. We therefore 
investigated the fate of endoplasmic reticulum-retained pathogenic mutants. Our data show 
that the mutants are retrotranslocated to the cytosol and degraded by the proteasome. In the 
presence of proteasomal inhibitors, three distinct un- or deglycosylated cytosolic species of 
vasopressin precursors were stabilized: pre-pro-vasopressin, pro-vasopressin, and an N-
terminally truncated form. In addition to the retrotranslocated forms, a fraction of the newly 
synthesized precursor was not translocated, but synthesized into the cytosol due to inefficient 
function of the vasopressin signal peptide. As a result, cytosolic pre-pro-vasopressin and its 
degradation product were also recovered when wild-type vasopressin was expressed. 
Cytosolic forms of vasopressin might trigger cytotoxicity in vivo, as has been proposed in the 
case of prion protein, which also contains an inefficient N-terminal signal peptide.  
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Introduction 
 
The antidiuretic hormone, arginine vasopressin, is synthesized in vasopressinergic neurons of 
the hypothalamus as a precursor consisting of three moieties (Fig. 11): the 19 amino-acid 
signal sequence, the nonapeptide hormone, the vasopressin-associated carrier protein 
neurophysin II (NPII), and a 39 amino-acid glycopeptide (copeptide) with a single N-
glycosylation site (Sausville et al., 1985). The precursor is cotranslationally targeted to the 
ER, where the signal is cleaved off by signal peptidase and the copeptide is core glycosylated. 
The prohormone contains a total of eight disulfide bonds. After complex glycosylation in the 
Golgi apparatus, the matured precursor is cleaved into its three moieties and targeted to 
secretory granules at the distal end of the axons. From there, the hormone is released into the 
circulation upon osmotic and non-osmotic stimuli. Vasopressin binds to its receptor on cells 
of the renal collecting duct, initiating a signaling cascade which leads to the mobilization of 
aquaporin-2 water channels, allowing regulated water reabsorption. Through this mechanism, 
vasopressin mediates the conservation of as much as ~20 l of fluid per day, thereby playing an 
important role in water homeostasis. 
Lack of circulating vasopressin causes diabetes insipidus. Affected individuals suffer 
from polyuria and polydipsia due to the inability to concentrate their urine. In rare cases, the 
condition is caused by mutations in the vasopressin gene and is inherited in an autosomal-
dominant manner (Rittig et al., 1996; Hansen et al., 1997). Over thirty mutations have been 
reported which alter the signal peptide (Ito et al., 1993; Rutishauser et al., 1996), the hormone 
(Gonking et al., 1997; Rittig et al., 2002), or the NPII moieties, respectively (Nijenhuis et al., 
1999; Rutishauser et al., 1999; DiMeglio et al., 2001; Fluck et al., 2001; Bullmann et al., 
2002; Santiprabhob et al., 2002; Boson et al., 2003). 
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FIG. 11. Wild-type and mutant vasopressin precursor and its signal sequence. The domain organization of 
the vasopressin precursor is shown with disulfide bridges as line connections and the glycosylation site as a 
diamond. The positions of mutations in mutant vasopressin precursors used in this study are indicated by an 
arrow. Below, the sequence of the signal peptide and the N-terminal portion of pro-vasopressin is shown. To 
prevent ER targeting, L(-9) of the signal peptide was mutated to R as indicated. 
 
 
Autosomal dominant neurohypophyseal diabetes insipidus (ADNDI) appears to be a 
neurodegenerative disease. Post-mortem histologic examinations revealed only few magno-
cellular neurons and scar tissue replacing much of the vasopressinergic nuclei (Hanhart, 1940; 
Gaupp, 1941; Braverman et al., 1965; Bergeron et al., 1991). A degenerative process specific 
to cells expressing the mutant protein would also explain the complete penetrance in 
heterozygous individuals (Mahoney et al., 2002) and the delayed onset of the symptoms 
weeks to months after birth. The neurodegeneration hypothesis was further supported by a 
study which showed decreased viability of cultured cells stably expressing mutant vasopressin 
(Ito and Jameson, 1997). A number of expression studies have shown that the mutant 
vasopressin precursors are retained in the ER (Olias et al., 1996; Beuret et al., 1999; Ito et al., 
1999; Nijenhuis et al., 1999; Siggaard et al., 1999; Evans et al., 2000). Together, the data 
suggest a cytotoxic effect of retained mutant precursors or of their degradation products. 
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We therefore studied the degradation of vasopressin mutants associated with ADNDI 
and found it to occur by the proteasomal machinery following retrotranslocation into the 
cytosol. Analysis of the degradation intermediates furthermore showed that a significant 
portion of the primary translation products fails to enter the ER lumen. Both pathways of 
degradation, via the ER lumen and directly from the cytosol, were also found to some extent 
for the wild-type protein. The cytotoxic effect of mutant vasopressin prohormone may result 
from processes that are quantitatively, but not fundamentally different from those occurring in 
cells expressing the wild-type protein. 
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Experimental Procedures 
 
Plasmids and constructs 
 
cDNAs for the wild-type vasopressin precursor and the mutants A(-1)T, ΔE47, and G57S 
were a gift from M. Ito (Northwestern University, Chicago, IL). The signal peptide of 
enkephalin was fused to wild-type and ΔE47 pro-vasopressin and, to delete the vasopressin 
hormone sequence, to the wild-type neurophysin II-glycopeptide sequence (in the same 
manner as described in (Cescato et al., 2000). Point mutations D(-17)R, L(-9)R, and 
R(8)E/K(11)E/R(12)E, were generated by polymerase chain reaction. All cDNAs were 
subcloned into the pRc/RSV expression plasmid (Invitrogen) and verified by DNA 
sequencing. 
 
 
Cell culture and transient transfection 
 
COS-1 and CV-1 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Sigma) 
supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 μg/ml streptomycin, 2 
mM L-glutamine at 37°C in 7.5% CO2. Neuro2A cells COS-1 cells were transiently 
transfected in 6-well plates using Lipofectine (Life Technologies, Inc.) and used 2–3 days 
after transfection. Neuro2a were grown in DMEM containing 4500 mg/l glucose in 5% CO2. 
They were transfected using Metafectene (Biontex Laboratories). To produce stably 
expressing cell lines, the cDNA of the vasopressin precursor was subcloned into the 
expression vector pCB6 and transfected into CV-1 cells using calcium phosphate 
precipitation. Clonal cell lines resistant to 0.5 mg/ml G418-sulfate were isolated and screened 
for pro-vasopressin expression by immunofluorescence. 
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Metabolic labeling and immunoprecipitation 
 
For labeling experiments, transfected cells were starved for 30 min in DMEM without 
cysteine and methionine (Sigma) supplemented with 2 mM L-glutamine. Cells were labeled 
for the times indicated with 100 μCi/ml [35S] protein labeling mix (DuPont-NEN) in 
starvation medium and chased in starvation medium supplemented with excess cysteine and 
methionine. Cells were transferred to 4°C, washed with phosphate-buffered saline (PBS), 
lysed in 500 μl of lysis buffer (PBS, 1% Triton X-100, 0.5% deoxycholate, 2 mM 
phenylmethylsulfonyl fluoride), and scraped. After 10 min centrifugation in a microfuge, the 
lysate was subjected to immunoprecipitation using rabbit polyclonal anti-neurophysin II or 
anti-vasopressin antibodies (ICN). The immune complexes were isolated with protein A-
Sepharose (Zymed) and analyzed by electrophoresis on 10% polyacrylamide Tris/trycine 
SDS-gels and autoradiography. For deglycosylation, immunoprecipitates were either boiled 
for 2 min in 50 µl 50 mM Na-citrate, pH 6, 1% SDS and incubated with 1 mU endo-β-N-
acetylglucosaminidase H (Roche Biochemicals) for 2 h at 37°C, or they were boiled in 100 µl 
0.1 M Na-phosphate, pH 6.8, containing 50 mM EDTA, 1% β-mercaptoethanol, 0.1% SDS 
and incubated with 0.25 U endoglycosidase F/N-glycosidase F (Roche Biochemicals) for 3 h 
at 37°C 
 
 
Protease inhibition 
 
Stock solutions of 10 mM N-Acetyl-leucyl-leucyl-norleucinal (ALLN), 1 mM lactacystin, 1 
mM pepstatin A (all from Sigma) in DMSO, and of 10 mM leupeptin (Roche Biochemicals) 
in water were prepared. For application to the cells, they were diluted into DMEM to final 
concentrations of 250 μM ALLN, 25 or 40 μM lactacystin, 100 μM leupeptin, and 5 μM 
pepstatin A. ALLN was added to the cells 90 min and lactacystin 10 min prior to the 
experiment and was freshly added to the starvation, labeling, and chase media. The lysosomal 
inhibitors leupeptin and pepstatin A were applied to the cells 16 h before the experiment and 
were present during all further incubations. 
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Cytosol extraction 
 
To separate the cytosol from microsomes, labeled cells were incubated at 4°C in swelling 
buffer (15 mM HEPES/KOH, pH 7.2, 15 mM KCl) supplemented with 2 mM 
phenylmethylsulfonyl fluoride and protease inhibitor cocktail (from a 500-fold concentrated 
stock of 1 mg/ml each of pepstatin A, leupeptin, chymostatin, antipain, and 5 mg/ml 
benzamidine, dissolved in 40% DMSO and 60% ethanol) for 15 min at 4°C, scraped, and 
centrifuged for 30 min at 136000×g. The supernatant containing the cytosol and the 
resuspended organelle pellet were subjected to immunoprecpitation and analyzed as above. 
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Results 
 
Proteasome inhibitors stabilize mutant vasopressin precursors and degradation 
intermediates 
 
To test the fate of wild-type and mutant pre-pro-vasopressin in COS-1 cells, transiently 
transfected cells were radiolabeled with [35S]methionine/cysteine for 1 h and chased with 
excess unlabeled methionine/cysteine for 0 or 6 h. Cells and media were subjected to 
immunoprecipitation using an antibody directed against neurophysin II followed by SDS-gel 
electrophoresis and fluorography (Fig. 2A, lanes 1–8). Upon pulse-labeling, wild-type protein 
and the mutants ∆E47 and G57S were found as a major species of ~21 kDa corresponding to 
N-glycosylated pro-vasopressin. The mutant A(-1)T, in which mutation of the last residue of 
the signal sequence causes inefficient signal cleavage (Ito et al., 1993), appeared as two major 
products corresponding to glycosylated pre-pro-vasopressin and pro-vasopressin. In all cases, 
additional faint bands in the range of~17–19 kDa were produced. After 6 h of chase, wild-type 
pro-vasopressin and the signal-cleaved fraction of the A(-1)T mutant were secreted into the 
medium. Since COS cells lack prohormone processing enzymes, intact glycosylated pro-
vasopressin of 21 kDa was recovered. Hardly any protein could be detected in the cells, 
indicating that the mutants ∆E47, G57S, and the uncleaved fraction of A(-1)T had been 
retained and degraded. 
To test for degradation via the ER-associated degradation pathway, the proteasomal peptide 
inhibitor N-acetyl-leucyl-leucyl-norleucinal (ALLN) was added to the medium 90 min before 
and during the pulse and the chase periods (Fig. 12A, lanes 9–16). ALLN stabilized the 
putative degradation intermediates of ~17–19 kDa for wild-type and mutant precursors, and to 
variable extent also the full-size, glycosylated band of the mutant precursors, consistent with 
proteasomal degradation of retained protein. This was confirmed by experiments using 
lactacystin, a more specific proteasomal inhibitor. Addition of 25 μM lactacystin stabilized 
low molecular weight forms that were indistinguishable from those seen with ALLN 
treatment (Fig. 12B). In contrast, a mixture of leupeptin and pepstatin A, two inhibitors of 
lysosomal degradation, had no stabilizing effect on the mutant ∆E47 (Fig. 12C). These results 
indicate that mutant pro-vasopressin as well as a fraction of wild-type pro-vasopressin is 
degraded by the proteasome in a process that involves intermediates of 17–19 kDa. 
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FIG. 12. Effect of proteasomal inhibitors on the stability of wild-type and mutant vasopressin precursors. 
Wild-type (wt) vasopressin precursor and the mutants G57S, ∆E47, and A(-1)T were expressed in COS-1 cells, 
labeled with [35S]methionine/cysteine for 1 h, and chased for 0 or 6 h without inhibitors (control) or in the 
presence of 250 μM ALLN (panel A), 25 μM lactacystin (panel B), or of the lysosomal inhibitors leupeptin and 
pepstatin A (LP; panel C), as described in Experimental procedures. Cells and media were subjected to 
immunoprecipitation using an antibody directed against neurophysin II, and immunoprecipitates were analyzed 
by SDS-gel electrophoresis and autoradiography. The apparent molecular weight of glycosylated pro-vasopressin 
of 21 kDa is indicated. Products of lower apparent molecular weight of ~17–19 kDa are pointed out by asterisks. 
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Three cytosolic degradation intermediates are stabilized in the presence of proteasome 
inhibitors 
 
In addition to the expected glycosylated pro-vasopressin and in the case of A(-1)T to 
glycosylated pre-pro-vasopressin, up to three different lower-molecular weight forms could be 
distinguished. To analyze potential precursor–product relationships, we performed a time-
course of labeling of cells expressing either wild-type or mutant ∆E47 vasopressin precursor 
in the presence or absence of ALLN (Fig. 13A). In addition to an increasing signal of 
glycosylated pro-vasopressin (form 1), the three smaller species (forms 2–4) appeared with 
distinct kinetics. Form 2 appeared with highest relative intensity after the shortest pulse times 
of 5 min. Form 3, however, appeared and increased in intensity in parallel with glycosylated 
pro-vasopressin. Form 4 only accumulated after 30–60 min and in the presence of ALLN. The 
same bands were observed using the more specific proteasome inhibitor lactacystin (Fig. 
13B). The patterns of products generated by wild-type and mutant precursors were 
qualitatively similar, indicating that they are not related to specific mutations. 
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FIG. 13. Time-course of appearance of different vasopressin precursor forms. COS-1 cells expressing wild-
type (wt) or ∆E47 mutant vasopressin precursor were labeled for 5–60 min with [35S]methionine/cysteine. Cells 
were incubated with proteasome inhibitor (+) before and during labeling as described in Experimental 
procedures or were untreated (–). ALLN (250 µM) was used as inhibitor in panel A, and lactacystin (40 µM) in 
panel B. Vasopressin products were immunoprecipitated and analyzed by SDS-gel electrophoresis and 
autoradiography. 
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To characterize the different forms, immunoprecipitates of ALLN-treated labeled cells 
expressing ∆E47 vasopressin precursor were incubated with endoglycosidase H or F (Fig. 
14A, lane 1–3). The 21-kDa form 1 was deglycosylated to an apparent molecular weight of 
~18 kDa corresponding to form 3. In contrast, the lower bands were insensitive to 
deglycosylation. This suggested that product 3 corresponds to un- or deglycosylated pro-
vasopressin and product 4 to a subsequent degradation intermediate lacking a short segment of 
the polypeptide at the N- or C-terminus. Upon immunoprecipitation using an antibody 
directed against the vasopressin hormone, form 4 was not recovered (Fig. 14A, lane 4), 
indicating that it lacks the hormone sequence at the N-terminus. 
 Based on its size, product 2 likely represents pre-pro-vasopressin, the primary 
translation product that had not been translocated to the ER lumen. For comparison, we 
expressed various mutant precursors to serve as size markers (Fig. 14B). A mutant with a 
nonfunctional signal sequence (L(-9)R; lane 2), in which an arginine disrupts the hydrophobic 
core, comigrated with form 2. Only a very small fraction was glycosylated but not processed 
by signal peptidase (arrowhead). A mutant lacking the signal peptide entirely (∆SP), i.e. pro-
vasopressin synthesized into the cytosol, migrated like band 3 (lane 3). In a further construct 
the hormone domain was deleted (∆VP) by fusing NPII-glycopeptide to the signal sequence of 
pre-pro-enkephalin. In addition to a glycosylated product of ~21 kDa, this construct also 
produced a 17-kDa form comigrating with band 4 (lane 4). Interestingly, this product of 17 
kDa was generated by all constructs, indicating that N-terminal clipping occurred 
independently of whether the protein was initially inserted into the ER or synthesized directly 
into the cytosol, and whether a signal sequence was still attached or not. 
 ER-associated degradation involves the retrotranslocation of unfolded or misfolded 
proteins from the ER lumen back to the cytosol where they are exposed to cytosolic N-
glycanase (Hirsch et al., 2003; Kostova and Wolf, 2003). To determine the localization of the 
low-molecular weight forms, cells expressing wild-type or ∆E47 vasopressin precursor were 
labeled for 1 h in the presence of ALLN, broken by swelling and scraping, and subjected to 
ultracentrifugation. We then analyzed the immunoprecipitated products in the membrane 
pellet (M) and the cytosol fraction (C) in comparison to the unfractionated total cell lysate (L; 
Fig. 14C). The experiment was performed with cells labeled for 5 min (lanes 1–3), producing 
predominantly form 2, or for 60 min (lanes 4–9), generating forms 3 and 4 in addition to  
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FIG. 14. Characterization of low molecular weight vasopressin products. Panel A: COS-1 cells expressing the 
vasopressin precursor mutant ∆E47 were incubated with ALLN, labeled with [35S]methionine/cysteine for 1 h, 
subjected to immunoprecipitation using anti-neurophysin II (αNP) or anti-vasopressin (αVP) antibodies and 
analyzed either directly (–) or after deglycosylation using endoglycosidase H (H) or endoglycosidase F (F). Panel 
B: COS-1 cells expressing the following mutant precursors were labeled for 30 min in the presence of ALLN and 
analyzed as above: ∆E47, the signal peptide mutant L(-9)R, the signal peptide deletion mutant ∆SP, and the 
mutant ∆VP which lacks the vasopressin hormone sequence. Panel C: COS-1 cells expressing wild-type or ∆E47 
mutant precursor as indicated were incubated with ALLN and labeled for 5 min to generate (besides form 1) 
predominantly form 2, or for 60 min to generate predominantly forms 3 and 4. The labeled cells were then 
broken by swelling and centrifuged at high speed. The supernatants containing cytosolic proteins (C) and the 
membrane pellets (M) were analyzed in parallel to unfractionated aliquots of total cell lysates by 
immunoprecipitation, gel electrophoresis and autoradiography. 
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glycosylated pro-vasopressin. The membrane fraction contained almost all of the glycosylated 
wild-type and mutant pro-vasopressin, whereas the smaller products were predominantly 
recovered in the cytosolic fraction. These products were therefore either retrotranslocated 
from the ER lumen or had never been targeted into the ER. 
 
 
The native signal peptide of vasopressin precursor is inefficient in ER targeting 
 
The occurrence of unglycosylated pre-pro-vasopressin indicates that the native signal 
sequence is inefficient in mediating translocation across the ER membrane. To test this, we 
expressed wild-type and ∆E47 mutant precursor with the native signal sequence in parallel 
with the same proteins containing the signal peptide of pre-pro-enkephalin. Upon labeling for 
3–60 min, form 2 was only produced by the constructs with the native vasopressin signal 
sequence, but not with the enkephalin signal (Fig. 15A). In contrast, forms 3 and 4 were 
generated with either signal, indicating that they are derived from form 1, glycosylated pro-
vasopressin in the ER lumen, after retrotranslocation. The fact that wild-type and ΔE47mutant 
proteins behaved identically indicates that the mutation is not responsible for the phenomenon 
and that the native signal of the vasopressin precursor is inherently inefficient. 
 The signal of the vasopressin precursor is unusual in that it contains a negative charge 
near the N-terminus (D(-17)) and is C-terminally followed by a cluster of positive charges  
(Fig. 15B). The enkephalin signal, in contrast, has a positive N-terminus and a longer 
hydrophobic core. To test whether the unusual charge distribution is responsible for inefficient 
translocation of the vasopressin precursor, D(-17) was mutated to R, or the residues R(8), 
K(11), and R(12) were mutated to E. However, upon expression of these charge mutants in 
COS-1 cells, the pre-pro-vasopressin form (form 2) was still detected (Fig. 15C). Inefficiency 
to translocate the protein is thus not, or not solely, due to the unusual charge distribution. 
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FIG. 15. Signal dependence of form 2 generation. Panel A: COS-1 cells expressing wild-type or mutant ∆E47 
precursor with either the native vasopressin signal (V) or the signal sequence of pre-pro-enkephalin (E) were 
incubated with ALLN and labeled for 3–60 min with [35S]methionine/cysteine before immunoprecipitation, gel 
electrophoresis and autoradiography. Panel B: The sequence of the enkephalin signal (E) fused to pro-
vasopressin (gray) is shown in comparison to the native vasopressin signal (V). Mutation of the charges flanking 
the hydrophobic core of the signal in constructs V(D>R) and V(RKR>EEE) are indicated. Panel C: COS-1 cells 
expressing the vasopressin precursor with the native signal (V), with the enkephalin signal (E), or with the 
charge mutants V(D>R) and V(RKR>EEE) were labeled for 5 min and analyzed as in A. 
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Missorting of pre-pro-vasopressin is not due to overexpression and also occurs in 
neuronal cells 
 
To exclude the possibility that mistargeting of pre-pro-vasopressin is simply a consequence of 
high-level expression in COS cells, we examined the polypeptides produced in stably 
transfected CV-1 cells, the parental cell line of COS-1 cells lacking the large T antigen 
driving the SV40 promoter/origin of replication present in our expression plasmids. In 
labeling and immunoprecipitation experiments, the stable CV-1 cell line expressing wild-type 
vasopressin precursor yielded a somewhat lower signal from the same number of cells than 
COS cells of which only 5–10% were transfected. The CV-1 cells are therefore producing at 
least 10–20 fold less of the protein per cell. Even in this situation, all three low molecular 
weight forms were made (Fig. 16A). In particular, form 2, pre-pro-vasopressin, was made as 
well. The inefficiency of the vasopressin signal is thus also apparent at moderate rates of 
synthesis.  
 In vivo, the vasopressin precursor is expressed by hypothalamic secretory neurons. We 
tested whether the products observed in fibroblasts were also generated in Neuro2a cells, a 
mouse neuroblastoma cell line that endogenously expresses secretogranin II and that had been 
shown to sort exogenous pro-opiomelanocortin into dense-core granules (Chevrier et al., 
1991). In transfected Neuro2a cells expressing wild-type or ∆E47 mutant vasopressin 
precursor and labeled for 5–60 min, pre-pro-vasopressin (form 2) and unglycosylated pro-
vasopressin (form 3) were detected and stabilized by ALLN as in COS-1 and CV-1 cells (Fig. 
16B). However, form 4 corresponding to N-terminally truncated pro-vasopressin could not be 
detected. Whereas the inefficiency of the vasopressin signal is observed in all cell types 
tested, the cytosolic protease responsible for N-terminal truncation of vasopressin precursors 
in COS-1 and CV-1 cells, is missing in Neuro2a cells. 
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FIG. 16. Generation of unglycosylated pre-pro-vasopressin (form 2) in a stable CV-1 cell line and 
transfected Neuro2a cells. A CV-1 cell line stably expressing the wild-type vasopressin precursor (panel A) and 
transiently transfected Neuro2a cells expressing wild-type (wt) or ∆E47 mutant precursor (panel B) were labeled 
for 5–60 min with [35S]methionine/cysteine with (+) or without (–) incubation with ALLN. Vasopressin products 
were immunoprecipitated and analyzed by SDS-gel electrophoresis and autoradiography. Open arrowheads 
indicate the absence of form 4 production in Neuro2a cells. 
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Discussion 
 
Degradation of vasopressin precursor occurs via proteasomes 
 
In cells expressing mutant vasopressin precursor, products of lower molecular weight than 
full-size glycosylated pro-vasopressin were stabilized by proteasomal inhibitors. No 
stabilization was observed with inhibitors of lysosomal proteases. This confirmed the 
expectation that the mutant proteins retained in the ER by the lumenal quality control system 
are subject to ER-associated degradation (ERAD), i.e. proteolysis by the cytosolic 
proteasome. Interestingly, significant stabilization of the same types of intermediates was also 
observed in cells expressing the wild-type protein. This may be due to a considerable number 
of polypeptides that never attained the native structure owing to errors in translation or post-
translational processes necessary for proper protein folding. It has previously been estimated 
that about one third of newly synthesized total protein is rapidly degraded (Schubert et al., 
2000). 
 Proteins targeted for proteasomal degradation are often, but not always, tagged by 
ubiquitin (Ciechanover, 1994; Hiller et al., 1996; Fisher et al., 1997; Zhou et al., 1998; 
Yewdell, 2001). We were unable to demonstrate ubiquitination of vasopressin polypeptides 
using multiple approaches, including immunoblotting of immunoprecipitated vasopressin 
precursor with anti-ubiquitin antibodies, increasing the cells' ubiquitin pool by overexpressing 
a ubiquitin cDNA, or coexpression of dominant-negative ubiquitin constructs (K48R and 
K48RG76A). It is unclear whether we did not reach sufficient amounts of ubiquitinated 
material, whether the ubiquitinated form might not be recognized by our antibodies, or 
whether the vasopressin mutants are targeted to the proteasome through alternative pathways, 
such as neddylation or sumoylation (Gong et al., 2000; Kamitani et al., 2001; Aguilar and 
Wendland, 2003). To detect ubiquitinylated proteins is notoriously difficult. In general only a 
small amount of the protein is detectable in ubiquitinated forms, which furthermore are 
heterogeneous in size. In addition, rapid deubiquitination may occur in cell lysates. 
 
 
 
 
Results                                                                                                                                      53 
___________________________________________________________________________ 
With proteasome inhibitors three unglycosylated forms accumulate in the cytosol 
 
 Upon incubation with proteasome inhibitors, three vasopressin precursor forms of molecular 
weights in the range of 17–19 kDa were stabilized (forms 2–4). All three of them were 
unglycosylated and cytosolic. Comparison of their electrophoretic mobility with that of 
different mutant vasopressin precursors, and immunoreactivity with antibodies directed 
against the hormone domain indicate that these forms correspond to unglycosylated pre-pro-
vasopressin (form 2), deglycosylated pro-vasopressin (form 3), and N-terminally truncated 
pro-vasopressin (form 4). Small amounts of form 3 have previously been observed in 
untreated cells (Beuret et al., 1999), but have been interpreted to be the product of incomplete 
glycosylation in the ER lumen. That this form is largely released into the supernatant of 
broken cells indicates that it has been retrotranslocated and deglycosylated. 
 The data support a scenario (illustrated in Figure 17) in which pre-pro-vasopressin is 
inserted into the ER, cleaved by signal peptidase, and modified to glycosylated pro-
vasopressin (form 1). Mutant proteins which are unable to fold into the native structure, but to 
some extent also wild-type polypeptides, are retrotranslocated to the cytosol and rapidly 
deglycosylated (form 3). In addition, a fraction of the translation products is not transported 
into the ER (form 2), based on the finding that the signal sequence was not cleaved and the 
protein remained unglycosylated. In the presence of proteasomal inhibitors, both forms 2 and 
3 may be N-terminally clipped to produce form 4 before degradation. The protease 
responsible for this slow clipping is unknown and appears to be expressed in a cell type 
specific manner, since form 4 was not detectable in Neuro2a cells. Cytosolic nonproteasomal 
proteases are known to be involved in the processing of antigenic peptides to be presented by 
MHC class I molecules (e.g. ER aminopeptidase associated with antigen processing, (Serwold 
et al., 2002)). 
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FIG. 17. Schematic summary of the products and degradation intermediates of vasopressin precursor. The 
majority of vasopressin precursor is translocated into the ER lumen, cleaved by signal peptidase and glycosylated 
to form 1 (glycosylated pro-vasopressin). Molecules unable to fold are retrotranslocated into the cytosol and 
deglycosylated to form 3 (deglycosylated pro-vasopressin). A fraction of precursor proteins (even of the wild-
type) is not translocated and is found as cytosolic pre-pro-vasopressin (form 2). Forms 2 and 3 are stabilized by 
proteasomal inhibitors. In COS-1 and CV-1 cells, but not in Neuro2a cells, they give rise to an N-terminally 
processed form 4. Primarily forms 2, 3, and 4 accumulate upon addition of proteasome inhibitors indicating that 
they are substrates of the proteasome (shown on the right). 
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The vasopressin signal functions inefficiently 
 
The production of pre-pro-vasopressin suggests that the native vasopressin signal is 
inefficient. This is not due to incomplete signal cleavage, since no glycosylated pre-pro-
vasopressin could be detected. In ADNDI mutants affecting the cleavage efficiency of the 
signal, such as A(-1)T (mutation of the cleavage site (Ito et al., 1993)) and ∆G227 (truncation 
of the signal; (Beuret et al., 1999)), glycosylated pre-pro-vasopressin is easily detected. A(-
1)T also revealed increased form 2 (Fig. 12A, lane 15, and Fig. 12B, lane 11), since 
retrotranslocated polypeptides add to those that were primarily synthesized into the cytosol. 
Therefore, the defect in the native vasopressin signal is due to inefficient targeting or 
translocation. The phenomenon is not an artefact of overexpression and potential saturation of 
the secretory route, since it is also observed in CV-1 cells expressing at least ten times less 
protein per cell. Moreover, it is detected in Neuro2a cells which have characteristics of 
neuroendocrine cells and is thus likely to occur also in vasopressinergic cells in vivo. 
 The charges flanking the hydrophobic core of signal sequences largely determine 
signal orientation in the ER translocation machinery (Goder and Spiess, 2001). Typically, the 
N-terminal portion of signal peptides is positively charged (the positive-inside rule; (von 
Heijne, 1990)), or at least more positive than the C-terminal flanking sequence (Hartmann et 
al., 1989). This is not the case for the vasopressin signal where the charge difference ∆(C–N) 
calculated according to the rules by Hartmann et al. (Hartmann et al., 1989) is +2. 
Surprisingly, however, the unusual charge distribution is not responsible for the translocation 
inefficiency: mutation of D(-17) to R or of R(8), K(11), and R(12) to E did not reduce the 
production of pre-pro-vasopressin despite an improved charge difference of 0 and -4, 
respectively. The efficiency of the enkephalin signal fused to pro-vasopressin is thus also not 
just due to the positive N-terminus. The hydrophobic core of the enkephalin signal is longer 
and more hydrophobic (in total and on average) than that of the vasopressin signal. This might 
account for more efficient recognition by signal recognition particle (Hatsuzawa et al., 1997). 
 Inefficient function of signal sequences is observed rarely. Plasminogen activator 
inhibitor-2 (PAI-2) is found as a secreted and a cytosolic form because of an internal, 
uncleaved signal that is inefficient both in binding signal recognition particle and in 
subsequent interaction with the translocation complex (Belin et al., 1996). Parathyroid 
hormone-related peptide (PTHrP) precursor is in part found as pre-pro-PTHrP in the cell and 
accumulates in nucleoli due to a nucleolar targeting signal (Amizuka et al., 2000). Although 
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this signal has a positive N-terminus, its C-terminal sequence is even more positively charged. 
In both cases, dual localization may reflect separate functions in different compartments. 
 Of special pathophysiological interest is the case of the prion protein (PrP). A 
particular misfolded conformation of PrP (PrPSc), which is favored by certain mutations in the 
protein, causes neurodegenerative disorders (prion diseases). The N-terminal signal of PrP is 
inefficient and membrane targeting of a fraction of the protein is rescued by a C-terminal 
hydrophobic sequence (Hölscher et al., 2001). PrP can adopt multiple membrane topologies, 
including a fully translocated form (SecPrP), two transmembrane forms with either the N- or 
the C-terminal portion of the polypeptide translocated into the ER lumen (NtmPrP and CtmPrP, 
respectively), and a cytosolic form (Hegde et al., 1998; Hegde and Rane, 2003). Again, the 
charge difference of the signal is the opposite of that typical for secretory signal peptides. It 
has been shown that mutant PrP as well as a significant portion of wild-type PrP is degraded 
via the proteasome, since cytosolic, unglycosylated forms accumulate upon treatment with 
proteasomal inhibitors (Ma and Lindquist, 2001; Yedidia et al., 2001). It has recently been 
proposed that the cytosolic forms of PrP trigger at least some neurodegenerative prion 
diseases, because expression of a cytosolic form of PrP lacking the N-terminal signal and the 
C-terminal glycosylphosphatidylinositol anchor sequence was toxic in Neuro2a cells and 
rapidly caused neurodegeneration in transgenic mice (Ma et al., 2002). In addition, conversion 
to a PrPSc-like conformation was found to be increased for a mutant PrP causing heritable 
prion disease correlating with its increased transport into the cytosol (Ma and Lindquist, 
2002). To which extent the situation of mutant vasopressin precursor parallels that of PrP 
remains to be determined. 
It is not known at present whether ADNDI results from a toxic product in the cytosol 
or in the ER lumen. Several factors that are induced by ER stress have been shown to mediate 
cell damage. The transcription factor CHOP has been shown to induce an apoptotic response 
in renal tubular cells of mice injected intraperitoneally with tunicamycin (Zinszner et al., 
1998), and downstream effectors of CHOP have been characterized (Wang et al., 1998). In a 
mouse model of non-autoimmune diabetes mellitus, hyperglycemia occurs as a consequence 
of apoptotic destruction of pancreatic β cells induced by ER stress due to ER retention of a 
mutant insulin precursor. Targeted deletion of CHOP delays the onset of diabetes in these 
mice (Oyadomari et al., 2002). Tunicamycin-induced apoptotic destruction of renal tubular 
cells is significantly alleviated in mice deficient in caspase-12, which is located at the ER and 
mediates ER-associated apoptosis in a specific manner (Nakagawa et al., 2000). Caspase-12 
also mediates amyloid-β-induced toxicity in primary cortical neurons cultured ex vivo, but is 
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not activated by non-ER-associated apoptotic signals, such as cycloheximide, tumor necrosis 
factor, or anti-Fas, again illustrating its specific role in ER-associated cell damage. 
 In ADNDI, cytotoxic pathways triggered by ER-retention directly and/or by 
retrotranslocated degradation intermediates in the cytosol may be involved in the degeneration 
of vasopressinergic neurons. Our findings indicate that proteasomal degradation of 
mistargeted precursors occurs even when two wild-type alleles are expressed. In heterozygous 
individuals, a critical concentration of toxic molecules may be exceeded, leading to neuronal 
degeneration. 
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General Discussion and Outlook 
 
In a subset of patients with DI, dominant-negative mutations in the gene of vasopressin, the 
anti-diuretic hormone, are responsible for the disease. Diverse mutations (Table I) lead to a 
similar phenotype, clinically characterized by polyuria and polydipsia. Post mortem 
examination of affected individuals revealed a hypocellularity and gliosis of vasopressinergic 
magnocellular neurons. The processes linking vasopressin deficiency and/or mutant precursor 
retention to eventual cell death have not been established and remain to be clarified. 
 
 
Misfolded vasopressin precursors are degraded by the proteasome 
 
Our metabolic labeling experiments demonstrated that vasopressin mutants (∆E47 and G57S 
completely, and A(-1)T partially) failed to exit the cell, as no protein was detected in the 
supernatant of transfected cells. Immunofluorescence staining showed the precursors to be 
localized to and retained in the ER. The material found in the ER remained there for only a 
short period of time, as pulse-chase experiments of mutant vasopressin failed to show a signal 
after a chase period of 6 hours. During this time, the bulk of the unreleased material must have 
been removed from the cell by a degradative mechanism. 
Experiments using different protease inhibitors suggested that the retained material is shuttled 
into the ERAD pathway and degraded by the proteasome. Inhibitors of the 26S proteasome, 
ALLN and lactacystin, used in different cell types (COS-1 and N2a) provide evidence that the 
improperly folded material is cleared from the cell via the proteasome. The use of pepstatin 
and leupeptin, inhibitors of the lysosome, did not stabilize mutant vasopressin precursor. 
Interestingly, the use of proteasomal inhibitors revealed that a considerable fraction of the 
precursor material is unable to enter the ER lumen, indicated by uncleaved signal peptide 
remaining attached to the precursor molecule. This was true not only for the diverse mutants 
examined, but also for the wild-type. Replacing the native signal peptide of vasopressin with 
the signal peptide of enkephalin enhanced ER translocation, inasmuch as no precursor with 
signal was detectable. The findings suggest an inefficiency of the vasopressin signal peptide 
in conferring translocation into the ER lumen. 
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Potential explanations for signal peptide inefficiency 
 
Poor transport of a nascent peptide chain into the ER can be due to different factors. Entry 
into the secretory pathway is initiated by the recognition of a hydrophobic stretch of amino 
acids in the signal peptide of a secretory protein by SRP. The hydrophobic stretch in the wild-
type vasopressin signal is shorter than in the more efficient enkephalin signal sequence 
(Figure 15 B). Decreased binding of SRP to the hydrophobic stretch in the signal peptide 
would reduce ER delivery. 
Another possibility has been brought up by Fons et al. (2003). Subsequent to targeting a 
nascent chain to the ER via SRP and its receptor, the protein needs to be translocated across 
the ER membrane. This gating step was re-enacted using purified components in a 
proteoliposome system (Gorlich and Rapoport, 1993). Fons et al. (2003) demonstrated that 
efficient targeting of nascent chains to the ER lumen may depend on TRAP. PrP exhibits poor 
targeting in proteoliposomes supplemented with the minimal translocation machinery. Import 
was improved with increasing amount of TRAP in the proteoliposomes. Different signal 
peptides fused to the PrP mature domain demonstrated an inverse relationship between TRAP 
dependence for ER import and the signal peptide’s ability to induce translocation, the signal’s 
gating strength (Kim et al., 2002). Only if the gating capability of the signal is very strong, 
does TRAP become dispensable. TRAP dependence could, however, not be linked to an 
obvious property of the signal peptide, such as overall length, length of the hydrophobic 
domain, or charge differential across the hydrophobic domain. Since the gating strength does 
not depend on a structural but rather on a functional parameter, comparison of signal 
sequences cannot provide a reliable prediction in this direction. A testing series analogous to 
Fons et al. (2003), using the vasopressin signal fused to PrP might help determine if this 
underlies the observed signal inefficiency. A construct bearing an enkephalin signal should 
thus exhibit a lower dependence on TRAP than one bearing the native vasopressin signal 
peptide. Low TRAP expression in magnocellular neurons could prevent efficient ER targeting 
of vasopressin precursor, predisposing the cells to an increase in mistargeted proteins if 
additional mutations occur. 
Finally, failure of the signal to properly orient the precursor in the translocon could prevent 
translocation. The unusual charge distribution of the vasopressin signal is in disagreement 
with von Heijne’s positive-inside rule. However, we have shown that this is not the main 
reason for inefficient targeting, since charge mutations in the signal did not abrogate the 
observed phenotype (Figure 15 C). Even a charge distribution favouring the translocation of 
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the C-terminal part of the precursor was not adequate to prevent the appearance of pre-pro-
vasopressin. The relatively short hydrophobic region would also not be a likely candidate for 
hindering reorientation of the signal from a head-on insertion to translocation of its C-
terminus. Extending the hydrophobic stretch by leucines was found to actually impede 
reorientation of pre-pro-vasopressin (Eusebio et al., 1998). 
 
 
Dominance and mechanisms of cell death in ADNDI 
 
Mutations in the vasopressin precursor leading to DI are dominant. The reason for this is most 
likely a cytotoxic effect generated by the mutant proteins. Successive loss of vasopressinergic 
magnocellular neurons leading to a declining quantity of secreted vasopressin corresponds to 
the progressive nature of the disease. The irreversible decline of hypothalamic cells would 
further account for the observed high penetrance. 
 
Several mechanisms may be responsible for cytotoxicity. The large variety of mutations 
described for vasopressin all produce a similar phenotype. This makes it improbable that each 
mutation is directly involved in toxicity. It appears more likely that they all act in a similar 
way to prevent normal folding and to generate a common misfolded toxic conformation. A 
dramatic example for a toxic protein is the prion protein which can adopt an extremely stable 
folding conformation leading to scrapie in sheep or Creutzfeldt-Jacob disease in humans by 
promoting the misfolding of normal prion protein. This novel conformation is inherently 
toxic, poisoning the host cell by interfering with essential processes. 
In general, misfolding of the protein due to mutations may cause toxicity in different ways. 
The protein may aggregate, induce autophagy, or overload the quality control and degradative 
mechanisms, all possibly cumulating in cell death. The cell uses chaperones to prevent the 
accumulation of misfolded proteins, and to keep unfolded proteins in solution. Terminally 
misfolded proteins are targeted for degradation to clear the cellular machinery of potentially 
toxic aggregates. Our experiments showed that expression of mutant vasopressin pro-hormone 
leads to formation of disulfide-linked aggregates (Beuret et al., 1999)(and unpublished). 
These aggregates were not observed when expressing wild type. Immunofluorescence studies 
showed no obvious ER deformation in transfected cells. Thus, aggregate formation may 
represent the beginning of neuronal toxicity. Eukaryotic cells use two major routes to remove 
undesired material. The ubiquitin-proteasome system removes short-lived nuclear and 
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cytosolic, as well as ER-synthesized proteins. The proteasome requires at least partial 
unfolding of the substrate for degradation to proceed and is, therefore, relatively inefficient at 
degrading aggregated proteins. Larger complexes and even whole organelles are degraded by 
the autophagy-lysosomal pathway. This involves the formation of double-membrane 
structures which eventually fuse with lysosomes. 
ER-synthesized proteins which are destined for degradation need to clear two hurdles if they 
are to be efficiently eliminated. Initially, they need to be extracted from the ER lumen, and 
subsequently shuttled to the proteasome for degradation. Inefficiency of the former process 
will lead to the deposition of material in the ER lumen, which is the hallmark of ER storage 
diseases (ERSD) (Kim and Arvan, 1998; Aridor and Hannan, 2000; Rutishauser and Spiess, 
2002). Russell bodies (RB) are dilated ER cisternae containing condensed immunoglobulins. 
Valetti et al (1991) demonstrated that synthesis of a mutated immunoglobulin which is neither 
secreted nor degraded is sufficient to induce formation of RB in different tissues among 
multiple species. RB membranes are separated from the ER lumen, and while the soluble BiP 
and PDI are excluded from these membranes, ribosomes and calnexin, both associated with 
membranes, are found on ER as well as on RB. Dilated cisternae are found in a number of 
secretory cells of different origin. This suggests that condensation of transport-incompetent 
proteins in the ER may be the common cause for these elements. One such example is the 
accumulation of mutated α1 anti-trypsin in hepatocytes in patients carrying the Z-variant 
allele (PiZ). Deposition of PiZ damages the hepatocytes, leading to liver disease (Carlson et 
al., 1989). 
How RB are ultimately disposed of is not clearly understood. One model suggests fusion of 
cisternae with lysosomes, another speculates on the formation of autophagic vesicles. In 
ADNDI, there is no evidence that RB might be formed in neuronal cells transfected with 
vasopressin mutants (Beuret et al., 1999; Nijenhuis et al., 1999; Friberg et al., 2004). This is 
illustrated by the fact that the addition of lysosomal inhibitors will neither cause accumulation 
of vasopressin precursor nor the formation of RB.  
Proteins which have been retrotranslocated but not degraded immediately run a high risk of 
aggregating in the cytosol. Integral membrane proteins endowed with highly hydrophobic 
regions are prime examples of such candidates. One well-studied paradigm is the Δ508 mutant 
form of the cystic fibrosis transmembrane conductance regulator (CFTR). Dislocation from 
the ER results in indigestible cytoplasmic aggregates which are ultimately sequestered to 
inclusion bodies termed aggresomes (Johnston et al., 1998). Aggresomes are found around the 
microtubule organizing center. Proteins are collected there by active minus end transport 
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along microtubules. Characteristic proteins found in aggresomes include the intermediate 
filament vimentin, molecular chaperones and proteasome subunits. The reason for 
sequestering aggregated proteins to a central cell site is not quite clear. It is thought that it 
might facilitate disposal of aggregates by an autophagic route, particularly in large 
mammalian cells such as neurons (Kopito, 2000). In post-mitotic cells effective clearance is 
very important because accumulation of material cannot be diluted by cell proliferation. 
Immunofluorescence and electron microscopy studies in stably transfected and differentiated 
neuronal cells, challenged by proteasomal inhibitors, might help determine if such a 
degradation pathway is followed by mutant vasopressin precursor as an alternate degradation 
route. Webb et al. (2003) found that α-synuclein, the major aggregate protein in Parkinson’s 
disease, was indeed degraded by both the proteasome and autophagy. 
Castino et al. (2005) introduced autophagy to the issue of cell debris degradation in ADNDI. 
Expression of the C67X mutant in rat and Neuro2a cells led to autophagic structures in the 
cell body, implicating the lysosome in the degradation process. The mutant caused the 
appearance of enlarged vesicles in the ER of transfected cells, confirmed by colocalization 
with calnexin and PDI. These markers set them apart from RB. A subset of C67X protein 
appeared to be found in the TGN, where it colocalized with the lysosomal marker cathepsin 
D. Inhibition of the autophagic-lysosomal pathway induced apoptosis of the mutant 
expressing cells, confirmed by the release of cytochrome c from mitochondria and the 
activation of caspases. Apparently, activation of autophagy serves as a survival mechanism to 
prevent cell death caused by the stress of mutant vasopressin precursor. In contrast, our 
findings did not demonstrate a role for the lysosome in vasopressin degradation. Their 
observation may thus indicate a step occurring at a later time point, perhaps as a result of the 
gradual build up of aggregated mutant vasopressin which obstructs the ER. 
Overloading the cellular control systems can have other detrimental effects. If traffic to the 
proteasome is impeded or if the amount of misfolded protein surpasses the degradative 
capacity of the ubiquitin-proteasome pathway, material will agglomerate in the cytosol. 
One interesting example is the cellular phenotype of mutations in the proteolipid protein gene 
which are responsible for a demyelination disease, Pelizeaeus-Merzbacher disease. These 
mutants lead to the accumulation of the gene products in the ER, causing ER stress. 
Eventually, the oligodendrocytes undergo apoptosis (Gow et al., 1998). In motor neuron 
disease, kinesin accumulates in sphere-like structures among massive accumulations of highly 
phosphorylated neurofilaments. These spheroids which impair anterograde transport in the 
axons of motor neurons are thought to result from disturbed transport of neurofilaments 
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(Toyoshima et al., 1998). One could speculate that mutation of the vasopressin wild-type 
which is already targeted inefficiently leads to an overload of the degradation pathway 
causing an accumulation of an ordinarily removed toxic intermediate form. Alternatively, 
overloading the degradation system may prevent the efficient removal of other proteins, 
allowing them to accumulate to toxic levels in the cell.  
 
Ideally, one would like to observe the fate of vasopressinergic neurons in vivo. Specific loss of 
magnocellular neurons in the hypothalamus is difficult to study. Mouse models offer evidence 
that the destruction of neurons occurs only among this subspecies of vasopressinergic 
neurons. This loss which Russell et al. (2003) were able to mimic in their knock-in mice was 
only observable in the C67X mutant mice. Those carrying the A(-1)T mutation, the most 
predominant among human patients, did not exhibit death of the corresponding magnocellular 
neurons. 
The mechanism of cell death itself is unclear in the animals. Accumulation of unfolded 
protein in the ER should invoke UPR. Failure to cope with the material present would then 
lead to ERAD and possibly to the induction of cell death via the expression of CHOP. Yet, 
C67X animals lacked an observable CHOP induction, perhaps due to the relatively small 
population of cells dying at any given time. 
 
A suitable system which permits the study of cell death in response to its exposition to mutant 
vasopressin precursor has remained intangible. Ito et al. (1997) had most closely achieved this 
goal. His Neuro2a neuroblastoma cell line exhibited reduced cell viability in differentiated 
cells expressing various mutant vasopressins, but not wild-type over a time period of six 
weeks. Our future goal is to build on their results and try to define a minimal toxic element of 
vasopressin precursor by stably expressing wild-type, several mutants, and selected tagged 
deletion constructs of vasopressin precursor in Neuro2a and rat hypothalamic cells. The toxic 
fragment would have to lie N-terminal of the shortest known truncation mutant found to date, 
C61X. To ensure comparable expression levels, all constructs will be transfected into the 
same mother cell line bearing a Flp recombination site. In parallel, we will examine the 
possible contribution of the inefficient signal to toxicity. The mutant coagulation factor X, 
“Santo Domingo”, causes a severe bleeding disorder. It is imported into the ER but its signal 
remains uncleaved (Racchi et al., 1993). Its recessive inheritance establishes it as a non-
cytotoxic control protein with failed trafficking properties. The enkephalin signal peptide-
bearing vasopressin precursor could serve as a control for efficient ER import. It will be 
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interesting to determine whether the enkephalin signal rescues or ameliorates the survival rate 
of otherwise toxic mutants, and whether these fusion constructs still induce aggregate 
formation. 
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